Inopha

Inopha, officially known as Nanjing Inopha Pharmaceutical Technology, is a clinical-stage biopharmaceutical company headquartered in Nanjing, China. The company specializes in the discovery and development of innovative small molecule drugs targeting immunology, inflammation, and metabolic disorders. Its lead candidate, INO-02, is a highly selective JAK1 inhibitor currently in Phase 2 clinical trials for atopic dermatitis and rheumatoid arthritis. Additionally, Inopha is advancing INO-08, a URAT1 inhibitor for gout and hyperuricemia, and INO-05, a TYK2 inhibitor for autoimmune conditions. The firm aims to address significant unmet medical needs through its proprietary R&D platform and strategic focus on validated biological pathways. Founded by industry veterans, Inopha leverages deep expertise in medicinal chemistry to build a competitive pipeline for the global market.